A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

Relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen
Measurable disease as described in the protocol
Received at least 1 prior line of therapy as described in the protocol
Must meet prior antimyeloma treatment parameters, as described in the protocol, and includes:
Received at least 2 consecutive cycles of lenalidomide or a lenalidomide-containing regimen
Refractory to lenalidomide
Exposed to a proteasome inhibitor (PI) alone or in combination with another agent
Had a response of partial response (PR) or better to prior therapy based on the investigator's determination of response as defined by International Myeloma Working Group (IMWG) criteria
Has t(11;14) status as described in the protocol and meets the following criteria:
For Part 1: MM participants independent of cytogenetic profile
For Part 2, Arm A: participant must be t(11;14) positive
For Part 2, Arm B: participant must be t(11;14) negative
An Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Adequate kidney, liver and hematologic laboratory values

Exclusion Criteria:

Previous treatment with venetoclax or other BCL-2 inhibitors, or previous treatment with pomalidomide
Known sensitivity to any IMiDs
Allogenic or syngeneic stem cell transplant within 6 months before the first dose of study drug or active ongoing graft versus host disease
Autologous stem cell transplant within 12 weeks before the first dose of study drug
Known meningeal involvement of MM